Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
Conditions
Interventions
None listed
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patientâ??s requiring Upfront Cytoreductive Surgery and Interval Cytoreduction after Chemotherapy 2. Cytology or Biopsy proven Epithelial Ovarian malignancies 3. Localized Metastasis on Imaging (CECT scans will be the most commonly used investigation, as per institutional protocol) 4. Good Performance status (KPS-100-40 or ECOG -0-2) 5. Age >18 yrs < 70 years (extremes of age is to be avoided due to anticipation of the morbidity of the surgery) 6. Preexisting co-morbid conditions that DONOT preclude CRS and HIPEC 7. ASA I to III
Exclusion criteria
Exclusion criteria: 1. Patient NOT consenting for Cytoreductive Surgery and HIPEC 2. Co morbidities that are a constant threat to the patientâ??s life 3. Poor performance Status and ASA IV and V 4. Study drop out
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CRS and HIPEC have a definitive role in the management of Epithelial Ovarian Cancers and CRP Kinetics help to predict postoperative morbid events or sub optimal surgery, compared to only WBC (Total Leukocyte) Counts.Timepoint: 1 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Post Operative Complications and Morbid Surgical Events, including 30 and 90 days MorbidityTimepoint: 90 days | — |
Countries
India
Contacts
Public ContactShouptik Basu
All India Institute of Medical Sciences, Patna
Outcome results
None listed